The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).
 
Wen Xia
No Relationships to Disclose
 
Zhongyu Yuan
No Relationships to Disclose
 
Shusen Wang
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pfizer
 
Qiufan Zheng
No Relationships to Disclose
 
Zhiyong Wu
No Relationships to Disclose
 
Muyi Zhong
No Relationships to Disclose
 
Fei Xu
No Relationships to Disclose
 
Ying Wang
No Relationships to Disclose
 
Xiaopeng Ma
No Relationships to Disclose
 
Shihui Ma
No Relationships to Disclose
 
Yuan-Qi Zhang
No Relationships to Disclose
 
Lehong Zhang
No Relationships to Disclose
 
Yanxia Shi
No Relationships to Disclose
 
Heng Huang
No Relationships to Disclose
 
Xiangdong Xu
No Relationships to Disclose
 
Haiyan Li
No Relationships to Disclose